Daily Biotech Investor Brief is a venture capital newsletter paid group product available on the Whop marketplace, created by narinderkumar and launched in November 2025.

Funding momentum in biotech remains selective but strong for companies with clear clinical paths. Aspen Neuroscience has closed a $115 million advance its iPSC-derived Parkinson’s therapy into later-stage development, reinforcing investor appetite for neurodegenerative programs with differentiated mechanisms. In oncology, Solve Therapeutics raised $120 million to scale its next-generation ADC platform, while Phrontline Biopharma secured $60 million to advance bispecific ADC candidates through early trials. Neuro-focused MindImmune Therapeutics added $10.2M to its Series A as it prepares a first-in-human study targeting immune-driven Alzheimer’s pathology—signaling growing interest in inflammation-based approaches beyond classic amyloid strategies. Meanwhile, Artios Pharma is expanding Phase 2 enrollment for its ATR inhibitor across pancreatic and colorectal cancer, positioning itself for key proof-of-concept data. Market conditions remain cautious: IPO windows are tight, valuations conservative, and early discovery startups still face headwinds. However, corporate venture arms—Novo, Lilly, Sanofi and others—are becoming dominant funders, favoring platform-rich biotechs with near-term catalysts. Investor Takeaway: Capital is concentrating in neuro and oncology programs with clinical momentum, compelling mechanisms, and scalable platforms. Watch for updates on MindImmune’s Phase 1 start, enrollment progress from DDR-targeting programs.

Daily Biotech Investor Brief currently has 1 active member and offers free access.

Daily Biotech Investor Brief offers a 30% affiliate commission for promoters. Track Daily Biotech Investor Brief's estimated revenue, member growth trends, and competitive market position on Whop Trends.